New Open MRI System from Fujifilm Combines Technology Advances with Patient Comfort
The Aperto Lucent open 0.4T MRI platform reportedly offers enhanced fat suppression and spatial resolution capabilities in addition to its open architecture design.
Emphasizing patient comfort, workflow efficiencies and enhanced imaging quality, Fujifilm has launched the Aperto Lucent open 0.4T magnetic resonance imaging (MRI) system.
The system’s wide laterally moving table and single-pillar design are key factors in promoting patient comfort, according to Fujifilm.
In addition to the platform’s permanent magnet technology, the company said the Aperto Lucent provides an array of features to facilitate efficient quality imaging.
In addition to promoting patient comfort, the Aperto Lucent open 0.4T MRI system reportedly provides enhanced fat suppression capabilities and improved spatial resolution. (Image courtesy of Fujifilm.)
• Fat suppression features include eight channels of active patient shimming and chemical shift-selective (CHESS) type radiofrequency (RF) fat saturation, which complements short tau inversion recovery (STIR) sequences.
• A combination of solenoid technology RF receiver coils and the IP-Recon iterative image reconstruction algorithm facilitate a high signal-to-noise ratio (SNR) and enhanced spatial resolution, according to Fujifilm.
• In order to address challenges with patient motion, Fujifilm said the Aperto Lucent system has RADAR motion compensating pulse sequence technology that reduces artifacts and the potential for rescans.
“APERTO Lucent is a perfect solution for providers looking for a space-saving, cost-effective system that enhances the MRI patient experience,” noted Shawn Etheridge, the executive director of modality solutions marketing for Fujifilm Healthcare Americas Corporation. “With permanent magnet open MRI technology, there is little need for additional equipment and infrastructure to maintain the magnetic field, keeping installation and operating costs low for our customers and providing a stronger return on investment.”
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
FDA Clears MRI-Based AI Segmentation of Organs at Risk During Radiation Therapy
May 2nd 2025Capable of segmenting over 37 organs and structures in the head, neck and pelvis, the MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.
